<DOC>
	<DOC>NCT01158079</DOC>
	<brief_summary>This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.</brief_summary>
	<brief_title>Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment</brief_title>
	<detailed_description>Study ALN-VSP02 is an extension study for previously conducted ALN-VSP02 studies. The study is being conducted to allow for continued ALN-VSP02 therapy for patients who completed participation in an ALN-VSP02 clinical study, achieved clinical benefit with ALN-VSP02 (i.e., disease response of stable disease or better), and, in the Investigator's opinion, may benefit from continuation of ALN-VSP02 therapy.</detailed_description>
	<criteria>1. Patient has completed a previous ALNVSP02 study, and is deemed to have stable disease or better. 2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 01. 3. Patient has adequate hematologic, liver, and renal function. 1. Patient is receiving fulldose (therapeutic) anticoagulation therapy and/or aspirin &gt; 325 mg/day or other platelet inhibitory agents. 2. Patient has clinically significant cardiovascular disease or uncontrolled serious cardiac arrhythmia. 3. Patient has clinically significant cerebrovascular disease. 4. Patient has a seizure disorder not controlled on medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Liver</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Advanced Solid Tumors with Liver Involvement</keyword>
</DOC>